where are we at at the moment ?, page-28

Unfortunately weazel is correct, and not downrapping just stating the obvious imo. Mozz, your efforts are extraordinary regards the science and many times your research has helped me stay the course when I’ve been ready to cut my losses….but to be honest mate, I’d love you to put your extraordinary skills to researching and reporting on the financial side of things. Clearly the board has zero idea of likely costs and financing options….though I’m hopeful our two white nights might lend some support here. Love to know how the costs for trials are determined? Do we make every effort to limit our costs? The numbers are mind blowing…Do we put too much emphasis on FDA approvals and can the drug be licensed elsewhere and begin earning revenue now? If so, we would essentially be getting real world (anecdotal) paid trial information….to help support a later FDA application? Do we need Big Pharma or MP funding, can we tap venture cap funding and can we bring the drug to market without any BP or MP involvement? Where does Bene sit and could a deal be struck with them if need be…..finance is all that matters now and any crystal balling of future share prices and revenue is totally contingent on our ability to remain funded….Love to hear your thoughts Mozz.